用于精准动脉粥样硬化诊疗的仿生纳米药物
Biomimetic nanomedicines for precise atherosclerosis theranostics.
作者信息
Tao Ying, Lan Xinmiao, Zhang Yang, Fu Chenxing, Liu Lu, Cao Feng, Guo Weisheng
机构信息
Department of Minimally Invasive Interventional Radiology, Key Laboratory of Molecular Target & Clinical Pharmacology, School of Biomedical Engineering & the Second Affiliated Hospital, Guangzhou Medical University, Guangzhou 510260, China.
School of Pharmaceutical Sciences, Capital Medical University, Beijing 100069, China.
出版信息
Acta Pharm Sin B. 2023 Nov;13(11):4442-4460. doi: 10.1016/j.apsb.2022.11.014. Epub 2022 Nov 15.
Atherosclerosis (AS) is a leading cause of the life-threatening cardiovascular disease (CVD), creating an urgent need for efficient, biocompatible therapeutics for diagnosis and treatment. Biomimetic nanomedicines (bNMs) are moving closer to fulfilling this need, pushing back the frontier of nano-based drug delivery systems design. This review seeks to outline how these nanomedicines (NMs) might work to diagnose and treat atherosclerosis, to trace the trajectory of their development to date and in the coming years, and to provide a foundation for further discussion about atherosclerotic theranostics.
动脉粥样硬化（AS）是危及生命的心血管疾病（CVD）的主要原因，因此迫切需要高效、生物相容的诊断和治疗方法。仿生纳米药物（bNMs）正日益满足这一需求，推动了基于纳米的药物递送系统设计的前沿发展。本综述旨在概述这些纳米药物（NMs）如何用于诊断和治疗动脉粥样硬化，追溯其迄今为止及未来几年的发展轨迹，并为进一步讨论动脉粥样硬化的诊疗一体化提供基础。
Zotero 插件